VANCOUVER, BC, Nov. 10, 2022 /CNW/ – Filament Health Corp. (OTCQB: FLHLF) (NEO: FH) (FSE: 7QS) (“Filament” or the “Company”), a clinical-stage natural psychedelic drug development company, released its second quarter financial results and operational highlights for the period ended September 30, 2022. “Our third quarter demonstrated Filament’s continued progress both internally and externally,”…
